1. In Vivo
  2. >>Global Vision

J&J Renews Commitment To Devices With Synthes Deal

Rumors that Johnson & Johnson was looking to exit cardiovascular devices and perhaps go so far as to divest their entire device business apparently can be put to rest in light of the company’s recently announced plans to acquire orthopedics leader Synthes Inc.

Rumors that Johnson & Johnson was looking to exit cardiovascular devices and perhaps go so far as to divest its entire device business apparently can be put to rest in light of the company's recently announced plans to acquire orthopedics leader Synthes Inc.[See Deal] The $21.7 billion deal – the largest acquisition in J&J's history – bolsters the company's lagging DePuy Synthes orthopedics division by enhancing its spine business and making it the leader in the trauma market, a relatively small but fast-growing orthopedic sector.

J&J's support for orthopedics is also notable for coming at a time when DePuy is facing internal challenges related to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.